Vitamin E and Alzheimer’s disease: What do we know so far?

Declan Browne, Bernadette McGuinness, Jayne V. Woodside, Gareth J. McKay*

*Corresponding author for this work

Research output: Contribution to journalReview article

2 Citations (Scopus)
62 Downloads (Pure)

Abstract

Vitamin E has been proposed as a potential clinical intervention for Alzheimer’s disease (AD) given the plausibility of its various biological functions in influencing the neurodegenerative processes associated with the condition. The tocopherol and tocotrienol isoforms of vitamin E have multiple properties including potent antioxidant and anti-inflam-matory characteristics, in addition to influences on immune function, cellular signalling and lowering cholesterol. Several of these roles offer a theoretical rationale for providing benefit for the treatment of AD-associated pathology. Diminished circulating concentrations of vitamin E have been demonstrated in individuals with AD. Reduced plasma levels have furthermore been associated with an increased risk of AD development while intake, particularly from dietary sources, may limit or reduce the rate of disease progression. This benefit may be linked to synergistic actions between vitamin E isoforms and other micro-nutrients. Nevertheless, randomised trials have found limited and inconsistent evidence of vitamin E supplementation as an effective clinical intervention. Thus, despite a strong rationale in support of a beneficial role for vitamin E for the treatment of AD, the evidence remains inconclusive. Several factors may partly explain this discrepancy and represent the difficulties of translating complex laboratory evidence and dietary interactions into clinical interventions. Methodological design limitations of existing randomised trials and restric-tions to supplementation with a single vitamin E isoform may also limit the influence of effect. Moreover, several factors influence individual responsiveness to vitamin E intake and recent findings suggest variation in the underlying genetic architecture attenuates vitamin E biological availability and activity which likely contributes to the variation in clinical responsiveness and the failure of randomised trials to date. Importantly, the clinical safety of vitamin E remains controversial and warrants further investigation.

Original languageEnglish
Pages (from-to)1303-1317
Number of pages15
JournalClinical interventions in aging
Volume14
DOIs
Publication statusPublished - 18 Jul 2019

Fingerprint

Vitamin E
Alzheimer Disease
Protein Isoforms
Tocotrienols
Tocopherols
Biological Availability
Disease Progression
Antioxidants
Cholesterol
Pathology
Safety
Food

Keywords

  • Alzheimer’s disease
  • Antioxidants
  • Tocopherols
  • Tocotrienols
  • Vitamin E

Cite this

@article{289667a88d8140edabdb377385583006,
title = "Vitamin E and Alzheimer’s disease: What do we know so far?",
abstract = "Vitamin E has been proposed as a potential clinical intervention for Alzheimer’s disease (AD) given the plausibility of its various biological functions in influencing the neurodegenerative processes associated with the condition. The tocopherol and tocotrienol isoforms of vitamin E have multiple properties including potent antioxidant and anti-inflam-matory characteristics, in addition to influences on immune function, cellular signalling and lowering cholesterol. Several of these roles offer a theoretical rationale for providing benefit for the treatment of AD-associated pathology. Diminished circulating concentrations of vitamin E have been demonstrated in individuals with AD. Reduced plasma levels have furthermore been associated with an increased risk of AD development while intake, particularly from dietary sources, may limit or reduce the rate of disease progression. This benefit may be linked to synergistic actions between vitamin E isoforms and other micro-nutrients. Nevertheless, randomised trials have found limited and inconsistent evidence of vitamin E supplementation as an effective clinical intervention. Thus, despite a strong rationale in support of a beneficial role for vitamin E for the treatment of AD, the evidence remains inconclusive. Several factors may partly explain this discrepancy and represent the difficulties of translating complex laboratory evidence and dietary interactions into clinical interventions. Methodological design limitations of existing randomised trials and restric-tions to supplementation with a single vitamin E isoform may also limit the influence of effect. Moreover, several factors influence individual responsiveness to vitamin E intake and recent findings suggest variation in the underlying genetic architecture attenuates vitamin E biological availability and activity which likely contributes to the variation in clinical responsiveness and the failure of randomised trials to date. Importantly, the clinical safety of vitamin E remains controversial and warrants further investigation.",
keywords = "Alzheimer’s disease, Antioxidants, Tocopherols, Tocotrienols, Vitamin E",
author = "Declan Browne and Bernadette McGuinness and Woodside, {Jayne V.} and McKay, {Gareth J.}",
year = "2019",
month = "7",
day = "18",
doi = "10.2147/CIA.S186760",
language = "English",
volume = "14",
pages = "1303--1317",
journal = "Clinical Interventions in Ageing",
issn = "1176-9092",
publisher = "Dove Medical Press Ltd.",

}

Vitamin E and Alzheimer’s disease : What do we know so far? / Browne, Declan; McGuinness, Bernadette; Woodside, Jayne V.; McKay, Gareth J.

In: Clinical interventions in aging, Vol. 14, 18.07.2019, p. 1303-1317.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Vitamin E and Alzheimer’s disease

T2 - What do we know so far?

AU - Browne, Declan

AU - McGuinness, Bernadette

AU - Woodside, Jayne V.

AU - McKay, Gareth J.

PY - 2019/7/18

Y1 - 2019/7/18

N2 - Vitamin E has been proposed as a potential clinical intervention for Alzheimer’s disease (AD) given the plausibility of its various biological functions in influencing the neurodegenerative processes associated with the condition. The tocopherol and tocotrienol isoforms of vitamin E have multiple properties including potent antioxidant and anti-inflam-matory characteristics, in addition to influences on immune function, cellular signalling and lowering cholesterol. Several of these roles offer a theoretical rationale for providing benefit for the treatment of AD-associated pathology. Diminished circulating concentrations of vitamin E have been demonstrated in individuals with AD. Reduced plasma levels have furthermore been associated with an increased risk of AD development while intake, particularly from dietary sources, may limit or reduce the rate of disease progression. This benefit may be linked to synergistic actions between vitamin E isoforms and other micro-nutrients. Nevertheless, randomised trials have found limited and inconsistent evidence of vitamin E supplementation as an effective clinical intervention. Thus, despite a strong rationale in support of a beneficial role for vitamin E for the treatment of AD, the evidence remains inconclusive. Several factors may partly explain this discrepancy and represent the difficulties of translating complex laboratory evidence and dietary interactions into clinical interventions. Methodological design limitations of existing randomised trials and restric-tions to supplementation with a single vitamin E isoform may also limit the influence of effect. Moreover, several factors influence individual responsiveness to vitamin E intake and recent findings suggest variation in the underlying genetic architecture attenuates vitamin E biological availability and activity which likely contributes to the variation in clinical responsiveness and the failure of randomised trials to date. Importantly, the clinical safety of vitamin E remains controversial and warrants further investigation.

AB - Vitamin E has been proposed as a potential clinical intervention for Alzheimer’s disease (AD) given the plausibility of its various biological functions in influencing the neurodegenerative processes associated with the condition. The tocopherol and tocotrienol isoforms of vitamin E have multiple properties including potent antioxidant and anti-inflam-matory characteristics, in addition to influences on immune function, cellular signalling and lowering cholesterol. Several of these roles offer a theoretical rationale for providing benefit for the treatment of AD-associated pathology. Diminished circulating concentrations of vitamin E have been demonstrated in individuals with AD. Reduced plasma levels have furthermore been associated with an increased risk of AD development while intake, particularly from dietary sources, may limit or reduce the rate of disease progression. This benefit may be linked to synergistic actions between vitamin E isoforms and other micro-nutrients. Nevertheless, randomised trials have found limited and inconsistent evidence of vitamin E supplementation as an effective clinical intervention. Thus, despite a strong rationale in support of a beneficial role for vitamin E for the treatment of AD, the evidence remains inconclusive. Several factors may partly explain this discrepancy and represent the difficulties of translating complex laboratory evidence and dietary interactions into clinical interventions. Methodological design limitations of existing randomised trials and restric-tions to supplementation with a single vitamin E isoform may also limit the influence of effect. Moreover, several factors influence individual responsiveness to vitamin E intake and recent findings suggest variation in the underlying genetic architecture attenuates vitamin E biological availability and activity which likely contributes to the variation in clinical responsiveness and the failure of randomised trials to date. Importantly, the clinical safety of vitamin E remains controversial and warrants further investigation.

KW - Alzheimer’s disease

KW - Antioxidants

KW - Tocopherols

KW - Tocotrienols

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=85069868492&partnerID=8YFLogxK

U2 - 10.2147/CIA.S186760

DO - 10.2147/CIA.S186760

M3 - Review article

AN - SCOPUS:85069868492

VL - 14

SP - 1303

EP - 1317

JO - Clinical Interventions in Ageing

JF - Clinical Interventions in Ageing

SN - 1176-9092

ER -